Replies to post #610052 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

He didn't know what he was talking about.

At this stage, we are only talking about solid tumors. As shown in Dr. Bosch's presentation, viral antigens were also found on dendritic cell surface. NWBO hasn't scratched the surface of anti-viral field yet. What if one day NWBO does a clinical trial like the following?

https://classic.clinicaltrials.gov/ct2/show/NCT03758625?cond=dendritic+cell+%2B+functional+cure&draw=2&rank=1;

He most likely didn't read the report on Prometheus.
https://s21.q4cdn.com/488056881/files/doc_presentations/2023/04/Splash-Investor-Event-Slides-FINAL-1.pdf

[dennisdave]

No I did not I based it on what Gilead paid for Immunomedics. Immunomedics as a biotech was very similar to NWBO's

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172048843;;
Saturday, June 03, 2023
n my view, Immunomedics can be well compared to NWBO

Just like NWBO Immunomedics was an almost zero (20 million) revenue biotech
Just like NWBO Immunomedics claimed to have a platform for solid tumors
Immunomedics catered to a much bigger market (Immunomedics Trodelvy is for breast cancer) than NWBO however with many more competitors.
Just like NWBO Immunomedics claimed Trodelvy can be used for all solid tumors
Just like NWBO Immunomedic had not started any meaningful P3 trial to provide evidence that Trodelvy is actually effective for all solid tumors

So with 1.5 billion shares O/S (1.1 now + 100 million max more dilution + 250 million for NWBO management) that would get us to around $ 16 per share buyout